Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL 4 and ABC transporter A3 towards intrinsic CML cell drug resistance
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Although BCR‐ABL 1 tyrosine kinase inhibitors reliably induce disease remission for patients with chronic myeloid leukaemia (CML), unlimited extension of therapy is necessary to prevent relapse from persistent leukaemic cells. Here, we analysed model cell lines and primary CML cells for the expression and functions of the ABC transporter A3 (ABCA 3) as well as the embryonic stem cell‐associated transcription factor SALL 4. ABCA 3 protected leukaemic cells from the cytotoxic effects of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. In the surviving cells, exposure to tyrosine kinase inhibitors significantly enhanced ABCA 3 expression in vivo and in vitro, and was associated with increased expression of SALL 4, which binds the ABCA 3 promoter. Inhibition of ABCA 3 or SALL 4 by genetic silencing or indomethacin, but not interferon gamma, interrupted SALL 4‐dependent regulation of ABCA 3 and restored susceptibility of leukaemic cells to tyrosine kinase inhibition. Tyrosine kinase inhibitor exposure facilitates a protective loop of SALL 4 and ABCA 3 cooperation in persistent leukaemic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · cited 2×
“…is a disease of the haematopoietic stem cell, and although specific inhibitors readily induce complete haematological and cytogenetic remission in most chronic-phase patients, evidence for persistent leukaemic cells has been observed in the majority of cases (Bhatia et al, 2003; Chu et al, 2011).”
BackgroundMa, Y., Cui, W., Yang, J., Qu, J., Di, C., Amin, H. M., Lai, R., Ritz, J., Krause, D. S., & Chai, L. (2006) · Blood · doi:10.1182/blood-2006-02-001594 · Cited by 215
A Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells
Yang, J., Gao, C., Chai, L., & Ma, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010766 · Cited by 152 · cited 1×
“…pluripotent and self-renewal properties in embryonic stem cells by interacting with NANOG First published online 21 February 2013 doi: 10.1111/bjh.12246 ª 2013 Blackwell Publishing Ltd British Journal of Haematology, 2013, 161, 204–213 research paper and OCT4 (POUSF1) (Yang et al, 2008, 2010).”
BackgroundInfluential
Cited by
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,167
Liu, L., Zhang, J., Yang, X., Fang, C., Xu, H., & Xi, X. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138515 · Cited by 67
RetractedKrchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
“ABCA3 dasatinib [7]; imatinib [7]; nilotinib [7] – –”
BackgroundSALL4: An Intriguing Therapeutic Target in Cancer Treatment
Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022) · Cells · doi:10.3390/cells11162601 · Cited by 35
“It is demonstrated that resistant to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib is associated with augmented levels of SALL4 and ABCA3 leading to formation of drug-resistance leukemic cell lines [51].”
Background
Metadata
- Authors
- Hupfeld, T., Chapuy, B., Schrader, V., Beutler, M., Veltkamp, C., Koch, R., Cameron, S., Aung, T., Haase, D., LaRosee, P., Truemper, L., & Wulf, G. G.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-02-21
- Volume
- 161
- Issue
- 2
- Pages
- 204-213
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2060415903
- Cited by
- 37
- References
- 4
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.